Serine/Threonine Kinase Assay Kits

CycLex Aurora-A kinase Assay / Inhibitor Screening Kit is designed to measure the activities of purified Aurora-A for the rapid and sensitive evaluation of inhibitors or activators.
Aurora-A kinase has been shown to contribute to oncogenic transformation and is frequently overexpressed and amplified in many human tumor types. It has been reported that amplification of Aurora-A in approximately 12% of primary breast tumors, as well as in breast, ovarian, colon, prostate, neuroblastoma, and cervical cancer cell lines.

Aurora-A Kinase Assay / Inhibitor Screening Kit　

CycLex Aurora Family Kinase Assay / Inhibitor Screening Kit is designed to measure the activities of purified Aurora family kinase, Aurora A, B and C kinase for the rapid and sensitive evaluation of inhibitors or activators.
Three distinct Aurora family members, termed Aurora A, B, and C, have been described in metazoan organisms. Significant interest in the subject was generated since all three Aurora kinases family members were reported to be overexpressed in many human cancers, and elevated expression has been correlated with chromosomal instability and clinically aggressive disease in some instances.

Aurora Family Kinase Assay / Inhibitor Screening Kit　

CycLex AMPK Kinase Assay Kit is designed to measure the activities of purified AMP-activated protein kinase (AMPK) or recombinant AMPK.
AMP-activated protein kinase (AMPK) regulates cellular energy metabolism by phosphorylation of key enzymes in metabolic pathways, such as acetyl–coenzyme A carboxylase (ACC) or mTOR (mammalian target of rapamycin). Adiponectin and leptin as well as hypoglycaemic drugs are activators of adipose tissue AMPK. This activation probably involves changes in the AMP/ATP ratio, and the upstream kinase LKB1. These results have led to the concept that AMPK has an interesting pharmaceutical potential in situations of insulin resistance (type 2 diabetes)

AMPK Kinase Assay Kit　

CycLex Rho-kinase Assay Kit is primarily designed to measure the activities of purified Rho-kinase and DMPK family kinases for the rapid and sensitive evaluation of inhibitors or activators.
Rao et al. (2001) investigated the role of Rho-kinase in the modulation of aqueous humor outflow facility. The treatment of human trabecular meshwork and canal of Schlemm cells with a Rho-kinase-specific inhibitor led to significant but reversible changes in cell shape and decreased actin stress fibers, focal adhesions, and protein phosphotyrosine staining. They suggested Rho-kinase as a potential target for the development of drugs to modulate intraocular pressure in glaucoma patients.

Rho-kinase Assay Kit　

CycLex Cyclic GMP Dependent Protein Kinase (cGK) Assay Kit is designed to measure the activities of purified cyclic GMP-dependent protein kinase (cGK) family of kinases for the rapid and sensitive evaluation of inhibitors or activators.
Activation of cGK is an important event in the regulation of blood pressure and platelet function. Upstream signals include the generation of nitric oxide (NO) by NO synthases and the subsequent rise in cGMP levels mediated by NO-dependent guanyl cyclases (GCs). The identification of new cGK activators by high throughput screening may lead to the development of a novel class of therapeutics for the treatment of cardiovascular diseases.

Cyclic GMP dependent protein kinase (cGK) Assay Kit　

CycLex Checkpoint Kinase Assay/Inhibitor Screening Kit-1 is designed to measure the activities of purified checkpoint kinase enzyme such as Chk1, Chk2 and C-TAK1 for the rapid and sensitive evaluation of checkpoint kinase inhibitors using recombinant checkpoint kinases. The phospho-specific monoclonal antibody used in this assay kit has been demonstrated to recognize the phospho-serine 216 residue in Cdc25C, which is phosphorylated by checkpoint kinases.

Checkpoint Kinase Assay / Inhibitor Screening Kit-1　

CycLex Pim-1 Kinase Assay / Inhibitor Screening Kit is designed to measure the activities of purified Pim-1 Kinase for the rapid and sensitive evaluation of inhibitors using recombinant Pim-1.
The pim-1 oncogene was originally identified as a genetic locus frequently activated by the proviral insertion of Moloney murine leukemia virus into mouse T cell lymphomas. The pim-1 oncogene has also been implicated in human hematopoietic malignancies, with its overexpression frequently detected in human hematopoietic cell lines as well as in fresh tumor cells from patients with leukemia.

Pim-1 Kinase Assay / Inhibitor Screening Kit　

CycLex AKT/PKB Kinase Assay / Inhibitor Screening Kit is designed to measure the activities of purified AKTs for the rapid and sensitive evaluation of inhibitors or activators.
Mammals have three closely related AKT genes, encoding the isoforms AKT1, AKT2 and AKT3. AKT1 was found to mediate insulin- and insulinlike growth factor (IGF-1)-induced cellular responses, such as the inhibition of glycogen synthase kinase-3, the stimulation of glucose uptake and the promotion of cell survival by inhibiting apoptosis. Overexpression of AKT1 or AKT2 is associated with some human ovarian, pancreatic, and breast carcinomas.

AKT/PKB Kinase Assay / Inhibitor Screening Kit　

CycLex CK2 Kinase Assay/Inhibitor Screening Kit designed to measure the activities of purified Casein kinase II (CK2) for the rapid and sensitive evaluation of inhibitors or activators. The phospho-serine specific monoclonal antibody used in this assay kit has been demonstrated to recognize the phospho-serine46 residue in p53, which is phosphorylated by CK2 in vitro.
The enzyme is highly expressed in most cancers and this higher expression has been tentatively correlated with the involvement of CK2 in the promotion of specific phases of the cell cycle.

CK2 Kinase Assay / Inhibitor Screening Kit　

CycLex CaM kinase II Assay Kit is primarily designed to measure the activities of purified Ca2⁺/Calmodulin dependent protein kinase II (CaM kinase II) for the rapid and sensitive evaluation of inhibitors or activators.
CaM kinase II is a ubiquitously expressed protein kinase that transduces elevated Ca²⁺ signals in cells to a number of target proteins ranging from ion channels to transcriptional activators. CaM kinase II has a unique holoenzyme structure and autoregulatory properties that allow it to give a prolonged response to transient Ca²⁺ signals and to sense cellular Ca²⁺ oscillations.

CaM Kinase II Assay Kit　

CycLex p38 Kinase Assay / Inhibitor Screening Kit is designed to measure the activities of purified p38 for the rapid and sensitive evaluation of inhibitors using recombinant p38.
Five homologues/isoforms of p38 MAPK have been identified: p38α, p38β, p38γ, p38δ and p38-2. The p38αMAPK pathway is crucial to inflammatory cytokine production and signaling. Several p38 MAPK inhibitors have been shown to block the production of interleukin-1, tumournecrosis factor and other cytokines. The inhibition of cytokine production seems to result from combined effects at the level of transcription and translation.

p38 Kinase Assay / Inhibitor Screening Kit　

CycLex IKK α and β Assay / Inhibitor Screening Kit designed to measure the activities of purified IKKα and IKKβ for the rapid and sensitive evaluation of inhibitors or activators.
IKK is a multisubunit complex that contains two catalytic subunits, IKKα and IKKβ, and the regulatory subunit IKKγ. Gene knock out studies have clearly demonstrated that IKKβ and IKKγ subunits of the IKK complex are required for NF-κB activation by all known pro-inflammatory stimuli including lipopolysaccharide (LPS), TNF, and IL-1. Thus a selective inhibitor of IKKβ would not only be of great interest as a potential anti-inflammatory agent but also as a valuable tool to understand the mechanisms regulating NF-κB activation by these inflammatory agonists.

IKK α and β Assay / Inhibitor Screening Kit　

CycLex Polo-like kinase 1 Assay / Inhibitor Screening Kit is designed to measure the activities of purified polo-like kinase 1 (Plk1) for the rapid and sensitive evaluation of inhibitors using recombinant Plk1.
Elevated expression of Plk1 occurs in many different types of cancer, and Plk1 has been proposed as a diagnostic marker for several tumors. Liu and Erikson used the vector-based small interfering RNA (siRNA) technique to specifically deplete Plk1 in cancer cells. They found that such depletion dramatically inhibited cell proliferation, decreased viability, and resulted in cell-cycle arrest with a 4n DNA content. The data supported the notion that disruption of Plk1 function could be an important application in cancer therapy.

Polo-like Kinase 1 Assay / Inhibitor Screening Kit